年轻单倍体相合供者对比年长匹配无关供者用于急性髓系白血病/骨髓增生异常综合征患者
该回顾性分析比较了接受年轻(≤35岁)单倍体相合供者移植(n=494)与年长(>35岁)匹配无关供者移植(n=1005)的急性髓系白血病/骨髓增生异常综合征患者结局。多变量分析显示年轻单倍体相合供者组总生存改善(HR 0.81,95%CI 0.69-0.95,p=.01),且II-IV级急性移植物抗宿主病、III-IV级急性移植物抗宿主病和慢性移植物抗宿主病发生率更低。作者结论支持在这类患者中采用年轻单倍体相合供者联合移植后环磷酰胺方案。
要点
- 年轻单倍体相合供者组总生存优于年长匹配无关供者组(HR 0.81,95%CI 0.69-0.95,p=.01)。
- 年轻单倍体相合供者组II-IV级急性移植物抗宿主病(HR 0.64)、III-IV级急性移植物抗宿主病(HR 0.37)和慢性移植物抗宿主病(HR 0.49)均更低。
- 接受减低强度预处理的患者中年轻单倍体相合供者组复发率更高(HR 1.49,95%CI 1.18-1.88,p=.001)。
核心结论
- 数据支持在骨髓增生异常综合征或急性髓系白血病患者中采用年轻单倍体相合供者联合移植后环磷酰胺方案,优于年长匹配无关供者联合传统预防方案。
- 作者认为需进一步研究供者年龄在采用移植后环磷酰胺预防的单倍体相合与匹配无关供者移植中的重要性。
研究设计与样本
- 回顾性分析比较骨髓增生异常综合征和急性髓系白血病患者接受年轻(≤35岁)单倍体相合供者移植(n=494)或年长(>35岁)匹配无关供者移植(n=1005)的结局。
- 单倍体相合供者组接受移植后环磷酰胺预防,匹配无关供者组接受传统移植物抗宿主病预防。
主要发现
- 多变量分析中,年轻单倍体相合供者使用与总生存改善相关(HR 0.81,95%CI 0.69-0.95,p=.01)。
- 年轻单倍体相合供者组II-IV级急性移植物抗宿主病(HR 0.64,95%CI 0.53-0.77,p<.001)、III-IV级急性移植物抗宿主病(HR 0.37,95%CI 0.25-0.53,p<.001)和慢性移植物抗宿主病(HR 0.49,95%CI 0.40-0.60,p<.001)发生率更低。
- 接受清髓性预处理的患者中两组复发率相似,但接受减低强度预处理的年轻单倍体相合供者组复发率更高(HR 1.49,95%CI 1.18-1.88,p=.001)。
- 年轻单倍体相合供者组移植后≥3个月的非复发死亡率显著更低(HR 0.59,95%CI 0.38-0.90,p=.02)。
临床怎么用
- 作者结论支持在骨髓增生异常综合征或急性髓系白血病患者中采用年轻单倍体相合供者联合移植后环磷酰胺方案,优于年长匹配无关供者联合传统预防方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Optimal donor selection is fundamental to successful allogeneic hematopoietic cell transplantation (HCT), and donor age influences survival after both matched unrelated donor (MUD) and haploidentical donor HCT. Though recent studies have shown similar outcomes between MUD and haploidentical HCT, it is unknown if outcomes differ following HCT with younger haploidentical donors compared to HCT with older MUDs. Therefore, we performed a retrospective analysis comparing outcomes of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients who underwent HCT with younger (≤35 years) haploidentical donors (n = 494) or older (>35 years) MUDs (n = 1005). Patients in the haploidentical and MUD groups received post-transplant cyclophosphamide (PTCy) and conventional graft-versus-host-disease (GVHD) prophylaxis, respectively. In multivariate analysis, use of younger haploidentical donors was associated with improved overall survival (hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.69-0.95, p = .01) and lower rates of grade II-IV acute GVHD (HR 0.64, 95% CI 0.53-0.77, p < .001), grade III-IV acute GVHD (HR 0.37, 95% CI 0.25-0.53, p < .001), and chronic GVHD (HR 0.49, 95% CI 0.40-0.60, p < .001). Relapse rates were similar among those who received myeloablative conditioning but were higher in patients of the younger haploidentical group who received reduced intensity conditioning (HR 1.49, 95%CI 1.18-1.88, p = .001). The younger haploidentical group had significantly lower non-relapse mortality ≥3 months post-HCT (HR 0.59, 95% CI 0.38-0.90, p = .02). Our data support the use of younger haploidentical donors with PTCy over older MUDs with conventional prophylaxis in patients with MDS or AML. Further studies on the importance of donor age in haploidentical and MUD HCT with PTCy prophylaxis are warranted.
引用
- Marcoux C, Marin D, Ramdial J, et al. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Am J Hematol. 2023. PMID: 36734029. doi:10.1002/ajh.26870
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。